focus -WSS

focus

author：fashion 2025-08-25 07:28:21 - browse：646

Rising drug prices —Medicare coverage from STAT — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start. APStock

WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start.

Medicare released an initial outline of how the program will work in March. Some parts, including the outline of how drugs would be selected for the negotiation process, were immediately final. The agency asked drug companies, patients, and other affected parties to weigh in on other parts about how the process would proceed, what factors would be considered, and how drugmakers would be held accountable.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care

Please enter a valid email address. Privacy Policy

The negotiation process was created last August in Democrats’ drug pricing reform law, and Medicare is supposed to select the first 10 drugs that will be subject to negotiation by Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Anesthesiologist group: stop taking Ozempic before surgery

focus

knowledge

WSS

EU regulator recommends expanding Mounjaro approval to obesity

My yearlong odyssey to get my son’s ADHD medication covered

NIH director takes cautious approach to Biden drug pricing priority

Independent physicians launch a new lobbying group

Affirmative action in medical school literally saved lives

NIH director takes cautious approach to Biden drug pricing priority

focus

focus

Sign up for D.C. Diagnosis

focus

Peter Hotez and the public health issue of online harassment

eGenesis tests gene

The cancer drug shortage isn’t new — and neither are the solutions

Medical leaders decry Supreme Court decision on affirmative action

State Dept. review finds Biden bears some blame for Afghanistan failures

After affirmative action ruling, medical educators look to 'holistic review'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Dewpoint Therapeutics lays off staff after losing partnerships

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Apple is now the first public company to be valued at $3 trillion

focus

Eli Lilly, Pfizer, and others want in on the online prescription market

Biotech venture capitalists face new demands from investors

Apple is now the first public company to be valued at $3 trillion

Heart attack and stroke risk calculators need revising

Independent physicians launch a new lobbying group

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

focus

knowledge

hotspot

explore